New Class, New Thinking, New Measures, New Weather Peak, Healthy New Year, New Start
Release time:
2021-05-21
News from our newspaper 2021 , Jianfeng Health Technology Company started a new round of contracted operations. The new management team further clarified its business ideas based on the actual situation of the company, and introduced a series of new management measures. The company's production and operation in the first quarter improved significantly.
Prior to this, Peak Health has made many explorations in strengthening its management. On this basis, the new management team has put forward the development idea of "Shrink Front and Highlight Key " . That is to say, the enterprise resources will focus on key varieties such as Jingzhi Cikang, Gutai capsule and grape seed extract soft capsule, and strive to turn them into fist products with single product sales of over 10 million, so as to drive the overall sales of peak health products from point to area. In terms of market expansion, key products will be publicized through various channels and angles to expand the influence of enterprises and products in consumer groups.
This year, the group company decided to transfer the original Chinese medicine decoction pieces of Jianfeng Health to the pharmaceutical company, which provided great convenience for the new team's new idea "landing " . In the first quarter, the peak health thought set up a new concept of "before disease, stop at the best " , and practice the long-term goal of corporate social responsibility. Calling on all enterprises not to care about personal gains and losses overnight, employee "condensed into a force, twisted into a rope " , forming a good working atmosphere. In terms of specific management measures, Jianfeng Health introduced the contract responsibility system in the investment promotion module, the tasks were implemented layer by layer, and the resources were tilted to high-performance employees, which stimulated the enthusiasm of employees.
Strengthening management, reducing costs and increasing efficiency is a major focus of Peak Health's work this year. In order to strengthen the control in the production process, the production workshop began to adjust the process layout, optimize the production steps, and strictly control the cost of each production link. In terms of human resources management, on the basis of the past, the organization has been further optimized. While the staffing is inclined to the production line, the in-depth development of "full marketing " has been strengthened. In the past, the working concept of "as both a manager, an operator and a salesman " has been more fully reflected. The management took the lead, all the staff took turns to undertake the cleaning work, used their spare time to help production, and assisted in completing the tasks of packaging, delivery, loading and unloading. In addition, starting from the details of daily management, we can save expenses from "small place " . For example, the number of employees who have their own vehicles has increased in recent years, and the number of employees who need to take the factory bus in a unified way has been greatly reduced. This year, the bus system has been reformed, saving nearly 100,000 yuan per year for this item alone.
This series of new measures has won the understanding and positive response of employees, and has also injected new vitality into the enterprise. At the end of the first quarter, peak health sales revenue increased 27% year on year, achieving the target progress. Among them, the sales of health care products increased by about 40% year on year, and the export business increased significantly over the same period, creating a good start for the whole year's work. The person in charge of the company said that the new working idea still needs to be tested by practice. With the development of the group company "three-year action plan for on-site management " , the management of the production site will be optimized in the next step, and the management concept of 6S will be deeply publicized and implemented in every specific link in combination with the policy of project system training, explore improvement measures for corporate deficiencies and shortcomings, and strive for another breakthrough in business performance. (Reporter Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page